Swedish Orphan Biovitrum AB (publ) to Acquire CTI Biopharma Corp Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Christopher Winston Uhde - SEB, Research Division - Analyst : Got an awful lot. So I'll ask a couple and then get back in the queue. The first question is sort of on financials here. So I haven't seen you -- you mentioned sort of short or near-term synergies, but I haven't seen anything about the impact on the outlook for 2023. So what can you say about that? And secondly, would you please help us quantify the level of synergies you see short term and long term? So let's say, to be specific coming year and then over the longer term. And then for the second question in terms of the Trex transaction structure, why was it a rights issue that was picked instead of a directed share issue? And then as it relates to that, would it be correct to assume these will be preferential rights? And would you convene an EGM, pre or post deal? I'm just trying to get a sense of when this will sort of stop being a question in the equity story over the short term?

Question: Alistair David Campbell - RBC Capital Markets, Research Division - Analyst : Actually, I'm going to start again with Momelotinib if I can. They've talked a lot about utility in patients that have anemia as a key differentiator versus the other JAKs that are approved. But also CTI put some very good data as last year on anemia and ACVR1. So I'm just intrigued to know how you think you're able to utilize that sort of fend off Momelotinib when it comes to market? And then just a bit of a follow-up on PACIFICA. I think CTR were having some recruitment issues. So just can you confirm when you think that trial is set to read out on its primary endpoint and also when you think it might read out for that secondary endpoint of overall survival. And then finally, can I just ask and just a clarification on the royalty situation. Could you just clarify all the royalty pay aways that exist on the product on VONJO? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. MAY 10, 2023 / 1:00PM, SOBIV.ST - Swedish Orphan Biovitrum AB (publ) to Acquire CTI Biopharma Corp Call

Question: Christopher Winston Uhde - SEB, Research Division - Analyst : Maybe you've kind of asked this, but I think this was kind of asked, but maybe we'll ask it in a slightly different way. So up to 50% of the value could be covered by a rights issue. So 0 to 50% is a big interval, what factors would impact that range? And is further M&A a factor? And I guess then also just what can you say about transaction fees and loan costs?